Anti-GDF-15 antibodies

US11725047B2 · kind B2 · utility

Assignee

• AVEO Pharmaceuticals, Inc. · US

Inventors

• Lorena Lerner · Newton, US
• Sandra Abbott · Boston, US
• Ailin Bai · Newton, US
• Ting Chen · Austin, US
• Maria Isabel Chiu · Boston, US
• Qing Liu · Acton, US
• Laura Poling · Boston, US
• Nianjun Tao · Watertown, US
• Solly Weiler · Newton, US
• Zhigang Weng · Cambridge, US
• William M. Winston, Jr. · Marlborough, US
• Jeno Gyuris · Lincoln, US

Key dates

• Filing date: Mar 19, 2020
• Grant date: Aug 15, 2023
• Expiry date: Mar 19, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N15/63
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.